EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes

Rizky Hidayaturahmah, Erin Khoerunisa, Nisa Yulianti Suprahman, Fia Novitasari

JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) · 07.04.2026 · 16 (1) · 1

DOI: 10.22146/jmpf.88590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), online erschienen am 07.04.2026. Verfasst von Rizky Hidayaturahmah und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapy for heart failure with reduced ejection fraction (HFrEF) patients is complex, involving several combinations of treatments, but there are still some problems, such as rehospitalization, reduced ejection fraction values, increased heart rate, and decreased quality of life. Ivabradine, a selective heart rate-lowering agent, offers adjunctive therapeutic benefits.

Objective

This study aims to determine the characteristics of HFrEF patients who received additional therapy with ivabradine and to determine how ivabradine affects their clinical outcomes.

Methods

This narrative review searched articles on PubMed, Cochrane Library, Google Scholar, and ScienceDirect. The research was limited to randomized controlled trial articles, observational studies, and cohorts with international and national English and/or Indonesian articles published in the last 10 years.

Results

Twenty-eight studies (n=36,765) met the problem formulation and inclusion criteria were analyzed. Patients receiving ivabradine were predominantly male (74.9%), aged 56-65 years (81.9%), and had a history of smoking. Most patients had heart rate ≥70 bpm (75.4%), LVEF ≤30% (55.3%), BMI ≥28 kg/m² (87.1%), and NYHA class II-III (85.5%). The addition of ivabradine to the clinical outcome of HFrEF patients reduces heart rate (15.7 bpm), blood pressure (SBP: -4.4 mmHg; DBP: -0.9 mmHg), rehospitalization, and mortality, while improving LVEF and stroke volume, and quality of life. Adverse effects included manageable bradycardia and transient visual disturbances.

Conclusion

Ivabradine effectively improves clinical outcomes in HFrEF patients as adjunct therapy, with significant benefits in cardiac function, symptom control, and prognosis.

Zitieren

APA

Hidayaturahmah, R., Khoerunisa, E., Suprahman, N. Y., & Novitasari, F. (2026). Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 16(1), 1. https://doi.org/10.22146/jmpf.88590

Vancouver

Hidayaturahmah R, Khoerunisa E, Suprahman NY, Novitasari F. Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 2026;16(1):1. doi:10.22146/jmpf.88590

BibTeX
@article{Hidayaturahmah2026,
  author = {Hidayaturahmah, Rizky and Khoerunisa, Erin and Suprahman, Nisa Yulianti and Novitasari, Fia},
  title = {Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes},
  journal = {JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {1},
  doi = {10.22146/jmpf.88590}
}
Kostenlos starten →